Findings from St. Jude Children's Research Hospital demonstrate that virtual memory T cells, a specialized group of immune cells, provide nonspecific immunity for infants early in life. The work stems ...

Several infants treated with autologous ex vivo gene therapy for newly diagnosed X-linked severe combined immunodeficiency (X-SCID) in a phase I/II trial have developed fully functioning immune ...

X-linked severe combined immunodeficiency disease (X-SCID) is a rare genetic disorder characterized by profound defects in T-cell, B-cell, and natural killer (NK) cell function, caused by mutations in ...

A gene therapy for a rare type of severe combined immunodeficiency (SCID) was safe and sufficiently restored T-cell immunity in an early trial, results from a phase I/II study showed. At a single ...

The cytokine receptor common gamma chain (γc) is shared among the receptors for interleukin (IL)-2, -4, -7, -9, -15, and plays a pivotal role in transmitting these cytokine signals. 1,2 Many of these ...

La Jolla, CA – New animal studies conducted at the Salk Institute for Biological Studies show that the only human gene therapy treatment to date considered to be largely successful, is, in fact, ...

A recent study conducted over seven years has streamlined the testing and diagnosis of newborns with severe combined immunodeficiency (SCID), facilitating early intervention ...

SCID is a genetic disorder impacting the immune system, making children highly susceptible to severe infections and illnesses, and without treatment, it can be fatal within the first 2 years of life.